FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washir

gton, D.C. 20549	OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden

0.5

hours per response:

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	2.		saction	3A. Dec	emed	4.	5. Number 6. Date Exercisable and 7. Title and							9. Number		11. Nature			
			T	able I							sposed of s, converti			Owned					
Common Stock 04/12/20:						2013	04/1	12/2013	S ⁽¹⁾		4,330(1)	D	\$19.6184	(2) 1	,324	D			
Common Stock 04/12/20						2013	13 04/12/2013		M ⁽¹⁾		4,330(1)	A	\$14.18	5	,654	D			
Common	Stock				04/12/2	2013	04/1	12/2013	S ⁽¹⁾		1,130(1)	D	\$19.6	1	,324	D			
Common	Stock				04/12/2	2013	04/1	12/2013	M ⁽¹⁾		1,130(1)	A	\$14.47	2	,454	D			
									Code	v	Amount	(A) or (D)	Price	Reporte Transa (Instr. 3	ction(s)		(Instr. 4)		
1. Title of Security (Instr. 3)					2. Transaction Date (Month/Day/Ye		Execu if any	A. Deemed kecution Date, any lonth/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of		Securit Benefic Owned	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership			
			Tab	le I - N	lon-Der	ivativ	e Sec	urities A	cquire	ed, [Disposed o	of, or E	Beneficial	ly Owne	d				
(City)	(5	State)	(Zip)										Perso	n ·				
(Street) CARLSBAD CA 92010															Form filed by One Reporting Person Form filed by More than One Reporting				
2855 GAZELLE COURT						_ 4.	If Amen	dment, Date	e of Orig	jinal F	Filed (Month/D		6. Individual or Joint/Group Filing (Check Applicable Line)						
C/O ISIS PHARMACEUTICALS, INC.						04	/12/20	13					3 7 1, 1	Legai and	General Co	ulisei			
(Last) (First) (Middle)									ınsactior	ı (Mo	nth/Day/Year)		below)	below) SVP, Legal and Ger		w)			
Name and Address of Reporting Person* O'NEIL PATRICK R.						_ <u>IS</u>	SIS PI	HARMA	<u>ACEU</u>	TIC	CĂĹS INC	[Ch	eck all appli Direct	cable)	10%	Owner er (specify			
l I. Name an	nd Address o	of Reporti	ing Person [*]					iame and i								g Person(s) to	issuer		

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Transaction of Code (Instr. Derivative			6. Date Exerc Expiration Da (Month/Day/\)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable			Amount or Number of Shares				
Employee Stock Option (right to buy)	\$14.47	04/12/2013	04/12/2013	М			1,130	01/02/2013	01/01/2016	Common Stock	1,130	\$0	8,270	D	
Employee Stock Option (right to buy)	\$ 14.18	04/12/2013	04/12/2013	M			4,330	01/01/2013	12/31/2015	Common Stock	4,330	\$0	11,670	D	

Explanation of Responses:

- 1. Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/30/2013.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.60 to \$19.65, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Remarks:

/s/Patrick R. O'Neil

04/15/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.